Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ACE527 ETEC Vaccine with dmLT Adjuvant
NCT01739231Phase 2Completed
- Sponsor
- PATH
- Start
- Sep 2012
- Primary completion
- Oct 2013
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ACE527, dmLT in enterotoxigenic Escherichia coli infection, sponsored by PATH. Started Sep 2012; status: completed.
02
Drugs
ACE527dmLT
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT01739231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01739231.